Ascendis Pharma A/S – NASDAQ:ASND
Ascendis Pharma A/S stock price today
$194.62
+57.12
+41.54%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Ascendis Pharma A/S stock price monthly change
-0.42%
month
Ascendis Pharma A/S stock price quarterly change
-0.42%
quarter
Ascendis Pharma A/S stock price yearly change
+8.18%
year
Ascendis Pharma A/S key metrics
Market Cap | 8.21B |
Enterprise value | 4.54B |
P/E | -7.11 |
EV/Sales | 88.72 |
EV/EBITDA | -9.31 |
Price/Sales | 74.35 |
Price/Book | 14.44 |
PEG ratio | 0.14 |
EPS | -8.87 |
Revenue | 329.02M |
EBITDA | -354.77M |
Income | -501.56M |
Revenue Q/Q | 185.49% |
Revenue Y/Y | 322.17% |
Profit margin | -1139.62% |
Oper. margin | -1097.85% |
Gross margin | 76.28% |
EBIT margin | -1097.85% |
EBITDA margin | -107.83% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAscendis Pharma A/S stock price history
Ascendis Pharma A/S stock forecast
Ascendis Pharma A/S financial statements
| Jun 2023 | 47.39M | -121.43M | -256.23% |
|---|---|---|---|
| Sep 2023 | 48.03M | -162.22M | -337.73% |
| Dec 2023 | 137.70M | -86.87M | -63.09% |
| Mar 2024 | 95.89M | -131.03M | -136.65% |
| Dec 2023 | 137.70M | -86.87M | -63.09% |
|---|---|---|---|
| Mar 2024 | 95.89M | -131.03M | -136.65% |
| Sep 2025 | 202.65M | 7.23M | 3.57% |
| Dec 2025 | 235.41M | 18.91M | 8.03% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 823823000 | 758.98M | 92.13% |
|---|---|---|---|
| Sep 2023 | 873213000 | 946.64M | 108.41% |
| Dec 2023 | 825587000 | 971.28M | 117.65% |
| Mar 2024 | 802504000 | 1.04B | 129.68% |
| Jun 2023 | -153.12M | 46.95M | -2.30M |
|---|---|---|---|
| Sep 2023 | -124.71M | 22.22M | 143.35M |
| Dec 2023 | -42.47M | 6.65M | -6.05M |
| Mar 2024 | -101.58M | 7.15M | 18.42M |
Ascendis Pharma A/S alternative data
| Aug 2023 | 797 |
|---|---|
| Sep 2023 | 797 |
| Oct 2023 | 797 |
| Nov 2023 | 797 |
| Dec 2023 | 797 |
| Jan 2024 | 797 |
| Feb 2024 | 797 |
| Mar 2024 | 879 |
| Apr 2024 | 879 |
| May 2024 | 879 |
| Jun 2024 | 879 |
| Jul 2024 | 879 |
Ascendis Pharma A/S other data
100.00%
0.00%
of ASND is owned by hedge funds
171
+0
61.95M
+3.58M
shares is hold by hedge funds
| Patent |
|---|
Application Filling date: 10 May 2022 Issue date: 25 Aug 2022 |
Grant Filling date: 29 Dec 2016 Issue date: 7 Jun 2022 |
Application Filling date: 17 Nov 2021 Issue date: 19 May 2022 |
Grant Filling date: 25 May 2016 Issue date: 12 Apr 2022 |
Grant Filling date: 29 Dec 2016 Issue date: 23 Nov 2021 |
Application Filling date: 25 Sep 2019 Issue date: 4 Nov 2021 |
Application Filling date: 25 Sep 2019 Issue date: 28 Oct 2021 |
Application Filling date: 25 Sep 2019 Issue date: 28 Oct 2021 |
Grant Filling date: 16 Apr 2014 Issue date: 14 Sep 2021 |
Grant Filling date: 8 Oct 2013 Issue date: 20 Apr 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 2 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 7 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 5 Sep 2023 | Q2 2023 Earnings Call Transcript |
Growth Is Priced Out Of Novo Nordisk
Ascendis Pharma: Rare Disease Player Is A Buy On Yorvipath Launch Trajectory
Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)
Ascendis Pharma: Danish Blockbuster Hunter
An Update On Ascendis Pharma's Path To Profitability
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Ascendis Pharma's Ambitious Vision 2030
Ascendis Pharma: Skytrofa Net Sales Not The Update Investors Are Waiting For
The Great Market Miscalculation: Pfizer's True Value Remains Untapped
-
What's the price of Ascendis Pharma A/S stock today?
One share of Ascendis Pharma A/S stock can currently be purchased for approximately $194.62.
-
When is Ascendis Pharma A/S's next earnings date?
Unfortunately, Ascendis Pharma A/S's (ASND) next earnings date is currently unknown.
-
Does Ascendis Pharma A/S pay dividends?
No, Ascendis Pharma A/S does not pay dividends.
-
How much money does Ascendis Pharma A/S make?
Ascendis Pharma A/S has a market capitalization of 8.21B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 421.2% to 266.72M US dollars.
-
What is Ascendis Pharma A/S's stock symbol?
Ascendis Pharma A/S is traded on the NASDAQ under the ticker symbol "ASND".
-
What is Ascendis Pharma A/S's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Ascendis Pharma A/S?
Shares of Ascendis Pharma A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Ascendis Pharma A/S's key executives?
Ascendis Pharma A/S's management team includes the following people:
- Dr. Birgitte Volck M.D., Ph.D. Senior Vice President and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs(age: 63, pay: $42,870)
-
How many employees does Ascendis Pharma A/S have?
As Jul 2024, Ascendis Pharma A/S employs 879 workers.
-
When Ascendis Pharma A/S went public?
Ascendis Pharma A/S is publicly traded company for more then 10 years since IPO on 28 Jan 2015.
-
What is Ascendis Pharma A/S's official website?
The official website for Ascendis Pharma A/S is ascendispharma.com.
-
How can i contact Ascendis Pharma A/S?
Ascendis Pharma A/S can be reached via phone at +45 70 22 22 44.
Ascendis Pharma A/S company profile:
Ascendis Pharma A/S
ascendispharma.comExchange:
NASDAQ
Full time employees:
879
Industry:
Biotechnology
Sector:
Healthcare
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 Ăź/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Tuborg Boulevard 12
Hellerup, 2900
Hellerup, 2900
CIK: 0001612042
ISIN: US04351P1012
CUSIP: 04351P101
